Abstract 335P
Background
ZV0203 is a pioneering pertuzumab ADC targeting Her2 positive tumors, utilizing a tubulin inhibitor as its payload connected via a stable, protease-cleavable valine-citrulline linker. In preclinical studies, ZV0203 outperformed Kadcyla and Enhertu across various CDX models, demonstrating notable antitumor efficacy without significant toxicity. GLP toxicity study revealed high tolerability for ZV0203, with an estimated therapeutic index of 35.
Methods
This open-label, multicenter, phase 1 dose-escalation trial was conducted to evaluate the dose-limiting toxicity (DLT), safety, PK, immunogenicity, and preliminary efficacy of ZV0203 in pts with Her2 positive advanced solid tumors. ZV0203 was injected intravenously from 0.3 to 3.6 mg/kg (Q3W) in a 3+3 design with accelerated titration for the starting dose. Phase 2a study further characterized the safety and preliminary tumor response at doses of 4.3 and 5.0 mg/kg among 9∼18 Her2 positive advanced pts with esophageal, colorectal or prostate cancers.
Results
As of April 25, 2024, phase 1 study has completed with an enrollment of 15 pts with various solid tumors (breast, colorectal, gastric, and lung), of which 9 pts had received prior Her2-targeted therapies. No DLTs and interstitial lung disease were observed. The most common treatment related adverse events (TRAEs) were primarily grade 1-2, including corneal epitheliopathy, elevated liver enzymes, dry eyes, and hematological effects such as neutropenia; five pts experienced grade 3 TRAEs, which were manageable. Among 14 response evaluated pts, the disease control rate (DCR) was 71.4% and 5 pts had partial responses (PR). At efficacious doses 2.7 and 3.6 mg/kg, 3 PR and 1 SD were observed with objective response rate (ORR) of 50% and DCR of 67%; among the 2 progression disease cases, one had received prior Her2-ADC (MMAE payload) treatment and another had new lesion of Her2 negative. PK results indicated excellent linker stability. Phase 2a enrollment is under way.
Conclusions
ZV0203, the first in class pertuzumab ADC, was well tolerated and demonstrated promising antitumor activity in heavily pretreated Her2 positive pts. The results support continued development.
Clinical trial identification
NCT05423977.
Editorial acknowledgement
Legal entity responsible for the study
Hangzhou Adcoris Biopharma Co., Ltd.
Funding
Hangzhou Adcoris Biopharma Co., Ltd.
Disclosure
Y. Huang: Financial Interests, Personal, Full or part-time Employment: Hangzhou Adcoris Biopharma Co., Ltd. Y. Lu: Financial Interests, Personal, Full or part-time Employment: Hangzhou Adcoris Biopharma Co., Ltd. X. Wang: Financial Interests, Personal, Full or part-time Employment: Hangzhou Adcoris Biopharma Co., Ltd. F. Wang: Financial Interests, Personal, Full or part-time Employment: Hangzhou Adcoris Biopharma Co., Ltd. X. Huang: Financial Interests, Personal, Full or part-time Employment: Hangzhou Adcoris Biopharma Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
322P - Incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021
Presenter: Alexandra Thomas
Session: Poster session 14
323P - SPEN: Unraveling breast cancer's genetic symphony — Prognostic significance and therapeutic insights
Presenter: Sameer Emeish
Session: Poster session 14
324P - Application of advanced machine learning techniques to improve prognosis in primary breast angiosarcoma
Presenter: Haya Kamal
Session: Poster session 14
Resources:
Abstract
325P - The clinical validity of histological grade in neoadjuvant treated breast cancer
Presenter: Sanna Steen
Session: Poster session 14
326P - Exploratory analysis of the association of systemic inflammation and breast cancer recurrence in the Optitrain randomised controlled trial
Presenter: Marlene Rietz
Session: Poster session 14
327P - Monitoring over time of pathological complete response to neoadjuvant chemotherapy in breast cancer patients through an ensemble vision transformers-based model
Presenter: Maria Colomba Comes
Session: Poster session 14
328P - Real-world evidence (RWE) of effectiveness and safety of TCHP regimen: INSIGHT-HER2BC trial interim results
Presenter: Daur Meretukov
Session: Poster session 14
329P - RANK/RANKL, ERBB-2: A putative dual targeting strategy in RANK+/Her2+ breast carcinomas patients
Presenter: Michalis Karamouzis
Session: Poster session 14
330P - Randomized phase II study of neoadjuvant chemotherapy with denosumab compared to chemotherapy alone in hormonal receptor-positive, HER2-negative premenopausal breast cancer patients
Presenter: Shereef Elsamany Mohammed
Session: Poster session 14
331P - Neoadjuvant intetamab in combination with standard chemotherapy for locally advanced HER2-positive breast cancer
Presenter: Mingxia Jiang
Session: Poster session 14